Accession Number: | 0001209191-20-045097 |
Date: | 2020-08-03 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
ARBUCKLE STUART A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-08-03 | M | 1,553 | a | $86.52 | 36,732 | direct | ||
COMMON STOCK | 2020-08-03 | S | 171 | d | $276.40 | 36,561 | direct | ||
COMMON STOCK | 2020-08-03 | S | 413 | d | $277.85 | 36,148 | direct | ||
COMMON STOCK | 2020-08-03 | S | 689 | d | $278.72 | 35,459 | direct | ||
COMMON STOCK | 2020-08-03 | S | 280 | d | $279.58 | 35,179 | direct | ||
COMMON STOCK | 2020-08-03 | 0 | $0.00 | 140 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 86.52 | 2020-08-03 | deemed execution date | M | 1,553 (d) | 2027-02-02 | common stock 1,553 | $86.52 | 3,107 | direct |
ID | footnote |
---|---|
f1 | transaction made pursuant to mr. arbuckle's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $276.40 (range $276.13 to $276.71). |
f3 | mr. arbuckle undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $277.85 (range $277.23 to $278.18). |
f5 | open market sales reported on this line occurred at a weighted average price of $278.72 (range $278.30 to $279.07). |
f6 | open market sales reported on this line occurred at a weighted average price of $279.58 (range $279.45 to $279.75). |
f7 | the option vests in 16 quarterly installments from 02/03/2017. |